PlumX Metrics
Embed PlumX Metrics

A pilot clinical study of Δ-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme

British Journal of Cancer, ISSN: 0007-0920, Vol: 95, Issue: 2, Page: 197-203
2006
  • 302
    Citations
  • 0
    Usage
  • 381
    Captures
  • 22
    Mentions
  • 1,397
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    302
    • Citation Indexes
      293
    • Policy Citations
      8
      • Policy Citation
        8
    • Patent Family Citations
      1
      • Patent Families
        1
  • Captures
    381
  • Mentions
    22
    • News Mentions
      11
      • News
        11
    • Blog Mentions
      9
      • Blog
        9
    • References
      2
      • Wikipedia
        2
  • Social Media
    1,397
    • Shares, Likes & Comments
      1,397
      • Facebook
        1,397

Most Recent News

No good evidence that ‘banned’ substances reliably destroy cancer cells in humans

What was claimed Cannabis oil destroys cancer cells but it has been banned by the US Food and Drug Administration (FDA). Our verdict There is

Article Description

Δ-Tetrahydrocannabinol (THC) and other cannabinoids inhibit tumour growth and angiogenesis in animal models, so their potential application as antitumoral drugs has been suggested. However, the antitumoral effect of cannabinoids has never been tested in humans. Here we report the first clinical study aimed at assessing cannabinoid antitumoral action, specifically a pilot phase I trial in which nine patients with recurrent glioblastoma multiforme were administered THC intratumoraly. The patients had previously failed standard therapy (surgery and radiotherapy) and had clear evidence of tumour progression. The primary end point of the study was to determine the safety of intracranial THC administration. We also evaluated THC action on the length of survival and various tumour-cell parameters. A dose escalation regimen for THC administration was assessed. Cannabinoid delivery was safe and could be achieved without overt psychoactive effects. Median survival of the cohort from the beginning of cannabinoid administration was 24 weeks (95% confidence interval: 15-33). Δ-Tetrahydrocannabinol inhibited tumour-cell proliferation in vitro and decreased tumour-cell Ki67 immunostaining when administered to two patients. The fair safety profile of THC, together with its possible antiproliferative action on tumour cells reported here and in other studies, may set the basis for future trials aimed at evaluating the potential antitumoral activity of cannabinoids. © 2006 Cancer Research.

Bibliographic Details

M. Guzmán; C. Blázquez; I. Galve-Roperh; C. Sánchez; G. Velasco; M. J. Duarte; J. Ravina; M. C. Rosa; L. González-Feria

Springer Science and Business Media LLC

Medicine; Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know